Expertise in
10
conditions

Dr. Jay Carlson

Obstetrics and Gynecology
SJC-Women's Oncology
2055 S Fremont Ave Ste 200, 
Springfield, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
SJC-Women's Oncology
2055 S Fremont Ave Ste 200, 
Springfield, MO 

Overview

Jay Carlson is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri.

Dr. Carlson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Lymphadenectomy, and Hysterectomy.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 226 clinical trials.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

SJC-Women's Oncology
2055 S Fremont Ave Ste 200, Springfield, MO 65804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

224 Clinical Trials

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Other
Study Phase: Not Applicable
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin
Study Phase: Phase 3
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab
Study Phase: Phase 2
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
View 9 Less Clinical Trials

9 Total Publications

Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Journal: Gynecologic oncology
Published: March 17, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Albert Bonebrake
Obstetrics and Gynecology
Expertise in
19
conditions
Dr. Albert Bonebrake
Obstetrics and Gynecology
Referral may be required

Grove Professional Pharmacy Inc

1001 E Primrose St, 
Springfield, MO 
 (2.0 miles away)
417-875-3000
Languages Spoken:
English
See accepted insurances

Albert Bonebrake is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. Dr. Bonebrake is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Oophorectomy, and Ureteroscopy.

Expertise in
14
conditions
Dr. Marcia Hernandez
Obstetrics and Gynecology
Expertise in
14
conditions
Dr. Marcia Hernandez
Obstetrics and Gynecology
Referral may be required

Office

2115 S Fremont Ave Ste 1100, 
Springfield, MO 
 (2.1 miles away)
417-820-3554
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marcia Hernandez is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. Dr. Hernandez is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, Vaginal Cancer, and Oophorectomy.

Expertise in
12
conditions
Dr. Ashley Valenzuela
Obstetrics and Gynecology
Expertise in
12
conditions
Dr. Ashley Valenzuela
Obstetrics and Gynecology
Referral may be required

Coxhealth-Gynecologic Oncology

3850 S National Ave, 
Springfield, MO 
 (2.2 miles away)
417-875-3065
Languages Spoken:
English
See accepted insurances

Ashley Valenzuela is an Obstetrics and Gynecologist practicing medicine in Springfield, Missouri. Dr. Valenzuela is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Neuroendocrine Carcinoma of the Cervix, Oophorectomy, and Salpingo-Oophorectomy.

Frequently Asked Questions about Dr. Jay Carlson

How do I make an appointment with Dr. Jay Carlson?

You can book an appointment with Dr. Jay Carlson by calling their office at 417-820-3554. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jay Carlson a top-rated expert for Ovarian Carcinosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jay Carlson is classified as an Distinguished expert for Ovarian Carcinosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jay Carlson specialize in?

While Dr. Jay Carlson is a Obstetrics and Gynecology, they have specific expertise in Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Testicular Yolk Sac Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Jay Carlson participate in research or clinical trials?

Yes. Dr. Jay Carlson has published 9 articles and abstracts on conditions like Ovarian Carcinosarcoma. You can view a list of Dr. Jay Carlson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carlson's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile